Croatia’s share indices extend gains thanks to Podravka, Adris
Ljubljana share indices end week up, Telekom Slovenije leads gainers
Most Sofia bourse indices fall, Fibank paces blue-chip losers
UPDATE 1 - Bulgarian regulator okays 6.5% hike in Dec natgas price
Zarneni Hrani Bulgaria boosts 9-mo cons net profit, revenue falls
Sep 20, 2023 15:36 EEST
September 20 (SeeNews) - Kiril Domuschiev, president and CEO of Bulgarian animal and human health and nutraceuticals company Huvepharma, plans to invest $5 million (4.67 million euro) through his family's fund Domuschiev Impact to establish a global anti-malaria centre.
The centre will ensure affordable access to life-saving anti-malarial medications in highly affected regions, Domuschiev Impact said in a press release on Tuesday. It will prioritise the development of competitive, non-profit, anti-malaria treatments based on research supported by the Bill & Melinda Gates Foundation.
The fund, in collaboration with the Clinton Global Initiative and others, will also invest in training small cooperative farmers in Africa to enhance sustainable animal protein production. Over five years, farmers will receive livestock management expertise, nutrition support, veterinary services and essential animal health products from Huvepharma, fostering food security and prosperity in challenging regions.
Domuschiev Impact is a fund aimed at driving global change through investments in science, innovation and people, facilitating sustainability across various sectors.
Huvepharma specialises in animal and human health, as well as nutraceutical products, which are distributed in over 100 countries. The company operates production facilities in France, Italy, Bulgaria and the U.S., focused on biotechnology, vaccines and veterinary medicines.
($ = 0.9334 euro)
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options